CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells

被引:0
|
作者
Delphine R. Boulbes
Gaurav B. Chauhan
Quanri Jin
Chandra Bartholomeusz
Francisco J. Esteva
机构
[1] The University of Texas MD Anderson Cancer Center,Departments of Breast Medical Oncology
[2] New York University Langone Medical Center,Division of Hematology
来源
关键词
CD44; Trastuzumab; HER2; Breast cancer; miRNA;
D O I
暂无
中图分类号
学科分类号
摘要
Resistance to HER2-targeted therapies remains a major obstacle in the treatment of HER2-overexpressing breast cancer. CD44, a putative breast cancer stem cell (CSC) marker, is overexpressed in trastuzumab-resistant breast cancer cells. While CSC-related genes may play a role in the development of trastuzumab resistance, conflicting results have been published about CSC response to trastuzumab. We hypothesized that CD44 contributes to trastuzumab resistance independently of its role as a CSC marker. We used trastuzumab-sensitive breast cancer cell lines and their trastuzumab-resistant isogenic counterparts to evaluate the role of CD44 in response to trastuzumab. miRNA and mRNA expression were analyzed using microarray chips. A gene set enrichment analysis was created and matched with response to trastuzumab in cells and patient samples. The proportions of CSC in trastuzumab-resistant cells were similar to or lower than in the trastuzumab-sensitive cells. However, CD44 expression levels were significantly higher in both trastuzumab-resistant cell lines and its knockdown led to an increased response to trastuzumab. The invasiveness and anchorage-independent growth of trastuzumab-resistant cells were higher and blocked by downregulation of CD44. Results also showed that CD44-related resistance to trastuzumab is regulated by miRNAs. We identified a CD44-related gene expression profile that correlated with response to trastuzumab in cell lines and breast cancer patients. CD44 mediates trastuzumab resistance in HER2-positive breast cancer cells independently of its role as a CSC marker and that this role of CD44 is partly regulated by miRNA.
引用
收藏
页码:501 / 513
页数:12
相关论文
共 50 条
  • [1] CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
    Boulbes, Delphine R.
    Chauhan, Gaurav B.
    Jin, Quanri
    Bartholomeusz, Chandra
    Esteva, Francisco J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (03) : 501 - 513
  • [2] High Level of CD44 Expression and Soluble CD44 Secretion Mediate Trastuzumab Resistance in HER2 Positive Breast Cancer.
    Jin, Q.
    Baek, J. M.
    Boulbes, D. R.
    Esteva, F. J.
    [J]. CANCER RESEARCH, 2011, 71
  • [3] Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab
    Chen, Si
    Zhang, Guoliang
    Liu, Yiwen
    Yang, Cuixia
    He, Yiqing
    Guo, Qian
    Du, Yan
    Gao, Feng
    [J]. FEBS JOURNAL, 2024, 291 (08) : 1719 - 1731
  • [4] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [5] Serum CD44 levels and overall survival in patients with HER2-positive breast cancer
    Jong-Min Baek
    Quanri Jin
    Joe Ensor
    Delphine R. Boulbes
    Francisco J. Esteva
    [J]. Breast Cancer Research and Treatment, 2011, 130 : 1029 - 1036
  • [6] Serum CD44 levels and overall survival in patients with HER2-positive breast cancer
    Baek, Jong-Min
    Jin, Quanri
    Ensor, Joe
    Boulbes, Delphine R.
    Esteva, Francisco J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) : 1029 - 1036
  • [8] Trastuzumab resistance accompanies vasculogenic mimicry in HER2-positive breast cancer cells
    Shimoda, Masafumi
    Hori, Ami
    Noguchi, Shinzaburo
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [9] Trastuzumab resistance accompanies vasculogenic mimicry in HER2-positive breast cancer cells
    Shimoda, Masafumi
    Noguchi, Shinzaburo
    [J]. CANCER SCIENCE, 2018, 109 : 311 - 311
  • [10] Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Chi Zhang
    Xuening Duan
    Ling Xu
    Jingming Ye
    Jianxin Zhao
    Yinhua Liu
    [J]. Breast Cancer Research and Treatment, 2012, 136 : 739 - 748